40-O-(2-hydroxyethyl)rapamycin in combination with exemestane or letrozole for use in the treatment of breast tumour

摘要

40-O-(2-hydroxyethyl)rapamycin (everolimus) is proposed for use in combination with exemestane or letrozole in the treatment of breast tumour. Disclosed is antiproliferative and antiangiogenic activity of 40-O-(2-hydroxyethyl)rapamycin when used in combination with another active agent or alone.